logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 10 of 10 Items
Showing 1 - 10 of 10 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...
Journal Article
|
Research

Target product profiles: tests for tuberculosis treatment monitoring and optimization

Gupta-Wright A, den Boon S, MacLean E, Cirillo DM, Cobelens F,  et al.
2023-11-01 • Bulletin of the World Health Organization
2023-11-01 • Bulletin of the World Health Organization
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and opt...
Journal Article
|
Commentary

Diagnostics to support the scaling up of shorter, safer tuberculosis regimens

Branigan D, Denkinger CM, Furin J, Heitkamp P, Deborggraeve S,  et al.
2023-07-31 • Lancet Microbe
2023-07-31 • Lancet Microbe
Journal Article
|
Commentary

The 1/4/6x24 campaign to cure tuberculosis quickly

McKenna L, Frick M, Angami K, Dubula V, Furin J,  et al.
2023-01-01 • Nature Medicine
2023-01-01 • Nature Medicine
Journal Article
|
Commentary

Access to paediatric formulations for the treatment of childhood tuberculosis

Nash M, Perrin C, Seddon JA, Furin J, Hauser J,  et al.
2020-12-01 • Lancet Child and Adolescent Health
2020-12-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Journal Article
|
Letter

Urine LAM diagnostics can close the deadly testing gap for TB

Deborggraeve S, Menghaney L, Lynch S, McKenna L, Branigan D
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Commentary

Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking

Guglielmetti L, Low M, McKenna L
2020-04-28
2020-04-28
Journal Article
|
Research

Public investments in the development of GeneXpert molecular diagnostic technology

Gotham D, McKenna L, Deborggraeve S, Madoori S, Branigan D
2021-08-31 • PLOS One
2021-08-31 • PLOS One
BACKGROUND
The GeneXpert diagnostic platform from the US based company Cepheid is an automated molecular diagnostic device that performs sample preparation and pathogen detection wit...
Journal Article
|
Review

New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC,  et al.
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and r...